Stifel Maintains Buy on Summit Therapeutics, Lowers Price Target to $38

Benzinga · 3d ago
Stifel analyst Dara Azar maintains Summit Therapeutics (NASDAQ:SMMT) with a Buy and lowers the price target from $45 to $38.